Stocktoria
Cryoport, Inc. CYRX
Cryoport, Inc. (CYRX) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $176.2M at a 44.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -1.74 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.336 |
| Retained earnings / assets | -0.901 |
| EBIT / assets | -0.048 |
| Equity / liabilities | 1.916 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CYRX | Cryoport, Inc. | 4/9 | 0.96 | 10.3 | +12.4% |
| PHAT | Phathom Pharmaceuticals, Inc. | 4/9 | — | — | +216.9% |
| SNDX | Syndax Pharmaceuticals Inc | 1/9 | -7.54 | — | +627.8% |
| STOK | Stoke Therapeutics, Inc. | 4/9 | 5.29 | — | +404.5% |
| MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | 1/9 | 1.29 | — | -28.3% |
| RYTM | RHYTHM PHARMACEUTICALS, INC. | 5/9 | -6.24 | — | +45.8% |
| LQDA | Liquidia Corp | 3/9 | -4.36 | — | +1031.2% |
About Cryoport, Inc.
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network. The company's products include Cryoport Express Shippers; Cryoport Elite; Cryoport Express Cryogenic HV3 Shipping System; Smartpak Condition Monitoring System and Tec4Med, an IoT-based monitoring solutions; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services; MVE Fusion cryogenic system, a self-sustaining cryogenic freezer; and MVE Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.
FAQ
Is CYRX financially healthy?
Cryoport, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does CYRX pay a dividend?
No, Cryoport, Inc. does not currently pay a dividend.
How profitable is CYRX?
In FY2025, Cryoport, Inc. had a net margin of 44.4% and a return on equity of 15.6%.
What is CYRX's P/E ratio?
Cryoport, Inc.'s trailing price-to-earnings (P/E) ratio is about 10.3×, based on its latest annual earnings.
What is the analyst price target for CYRX?
The average Wall-Street price target for Cryoport, Inc. is $15.61, about 5.5% above the recent price, from 9 analysts.
Is CYRX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Cryoport, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone, a P/E of about 10.3×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.